Zobrazeno 1 - 10
of 54
pro vyhledávání: '"low‐grade ovarian cancer"'
Autor:
Alicja Ogrodniczak, Janusz Menkiszak, Jacek Gronwald, Joanna Tomiczek-Szwiec, Marek Szwiec, Cezary Cybulski, Tadeusz Dębniak, Tomasz Huzarski, Aleksandra Tołoczko-Grabarek, Tomasz Byrski, Katarzyna Białkowska, Karolina Prajzendanc, Piotr Baszuk, Jan Lubiński, Anna Jakubowska
Publikováno v:
Hereditary Cancer in Clinical Practice, Vol 20, Iss 1, Pp 1-8 (2022)
Abstract Background There are several genes associated with ovarian cancer risk. Molecular changes in borderline ovarian tumor (BOT) indicate linkage of this disease to type I ovarian tumors (low-grade ovarian carcinomas). This study determined the p
Externí odkaz:
https://doaj.org/article/f58574f1d3e2464bb1b27b149d164bac
Publikováno v:
Cancer Medicine, Vol 10, Iss 10, Pp 3373-3387 (2021)
Abstract Objectives Treatment of both platinum resistant high grade (HG) and low‐grade (LG) ovarian cancer (OVCA) poses significant challenges as neither respond well to conventional chemotherapy leading to morbidity and mortality. Identification o
Externí odkaz:
https://doaj.org/article/dcb692ee6aeb4eaa9306ab0136c8ad05
Autor:
Paweł Sadłecki, Marek Grabiec, Dariusz Grzanka, Jakub Jóźwicki, Paulina Antosik, Małgorzata Walentowicz-Sadłecka
Publikováno v:
Journal of Ovarian Research, Vol 12, Iss 1, Pp 1-10 (2019)
Abstract Low-grade ovarian cancers represent up to 8% of all epithelial ovarian carcinomas (EOCs). Recent studies demonstrated that epithelial-mesenchymal transition (EMT) is crucial for the progression of EOCs. EMT plays a key role in cancer invasio
Externí odkaz:
https://doaj.org/article/21c47334ecc149a4bccc41a714daf5d4
Publikováno v:
Cancer Medicine, Vol 10, Iss 10, Pp 3373-3387 (2021)
Cancer Medicine
Cancer Medicine
Objectives Treatment of both platinum resistant high grade (HG) and low‐grade (LG) ovarian cancer (OVCA) poses significant challenges as neither respond well to conventional chemotherapy leading to morbidity and mortality. Identification of novel a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54f6eb04443b84caafd33d3591ee51c3
https://doaj.org/article/dcb692ee6aeb4eaa9306ab0136c8ad05
https://doaj.org/article/dcb692ee6aeb4eaa9306ab0136c8ad05
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lucia Musacchio, Anna Amela Valsecchi, Vanda Salutari, Giorgio Valabrega, Floriana Camarda, Valentina Tuninetti, Gaia Giannone, Michele Bartoletti, Claudia Marchetti, Sandro Pignata, Anna Fagotti, Giovanni Scambia, Massimo Di Maio, Domenica Lorusso
Low grade serous carcinoma of the ovary and peritoneum (LGSC) is characterized by low response rates to chemotherapy and by MAPK pathway alterations. Phase II/III clinical trials tested different MEK inhibitors (MEKis) in this complex malignancy, wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f3ff6a9a9b17d9086e37f3dec54d9ba
https://hdl.handle.net/10807/219720
https://hdl.handle.net/10807/219720
Autor:
Alicja Ogrodniczak, Janusz Menkiszak, Jacek Gronwald, Joanna Tomiczek-Szwiec, Marek Szwiec, Cezary Cybulski, Tadeusz Dębniak, Tomasz Huzarski, Aleksandra Tołoczko-Grabarek, Tomasz Byrski, Katarzyna Białkowska, Karolina Prajzendanc, Piotr Baszuk, Jan Lubiński, Anna Jakubowska
Publikováno v:
Hereditary cancer in clinical practice. 20(1)
Background There are several genes associated with ovarian cancer risk. Molecular changes in borderline ovarian tumor (BOT) indicate linkage of this disease to type I ovarian tumors (low-grade ovarian carcinomas). This study determined the prevalence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb69edcd13b4305e0f983426aac7a8ad
https://pubmed.ncbi.nlm.nih.gov/35313928
https://pubmed.ncbi.nlm.nih.gov/35313928
Autor:
Skupin, Luisa
Borderline-Tumore des Ovars (BOT) machen 8-20% der epithelialen Ovarialtumore aus. Patientinnen erkranken im Durchschnitt 10 Jahre früher an BOT als EOC. Die allgemeine Prognose ist günstig, Rezidive treten allerdings zu 40% erst nach >5 Jahren auf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb7f513ef9a025bf966f9a489428cf48
https://refubium.fu-berlin.de/handle/fub188/31315
https://refubium.fu-berlin.de/handle/fub188/31315
Autor:
Grabowski, Jacek Przemysław
Der low-grade Subtyp gehört zwar zur Minderheit der Ovarialkarzinome, und stellt aber auf Grund seiner spezifischen Eigenschaften und fehlender neuer Therapieoptionen eine große klinische Herausforderung dar. Wegen der Seltenheit sind Studien nur s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::806b5c914e1966ed6a646ee2fa8476fc
https://refubium.fu-berlin.de/handle/fub188/31324
https://refubium.fu-berlin.de/handle/fub188/31324